What is the 13F Pro Quality Score for CAMP?

13F Pro ranks Camp4 Therapeutics Corp (CAMP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CAMP's current score at https://13fpro.ai/research/CAMP (free sign-up required for the full ranking).

Which hedge funds own the most CAMP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CAMP include JANUS HENDERSON GROUP PLC, 5AM Venture Management,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CAMP as soon as new 13F filings post.

Where does 13F Pro source CAMP data?

All Camp4 Therapeutics Corp fundamentals and ownership data come directly from SEC EDGAR. Camp4 Therapeutics Corp files with the SEC under CIK 1736730. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CAMP in?

Camp4 Therapeutics Corp (CAMP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CAMP research updated on 13F Pro?

CAMP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Camp4 Therapeutics Corp(CAMP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1736730 CAMP stock profile & AI dashboard →

13F Pro Quality Score

23.3/100

Rank #2,617 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

2.1/100

Balance Sheet

3.4/100

Earnings Quality

30.0/100

Free Cash Flow

2.0/100

Institutional Flow

12.3/100

Revenue Scale

2.1/100

Dilution Risk

2.9/100

CAMP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Camp4 Therapeutics Corp (CAMP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CAMP at 23.3/100 on a 32-signal composite quality model, placing it at rank #2,617 of 2,879 stocks — the bottom half of the AI-ranked universe. CAMP scores in the top quartile across revenue growth (97.5). Areas of concern include free cash flow (2.0) and profitability (2.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Camp4 Therapeutics Corp reports quarterly revenue of $1.3M, net income of $-18.3M, free cash flow of $-11.0M. Top institutional holders of CAMP by reported 13-F value include JANUS HENDERSON GROUP PLC, 5AM Venture Management,, FMR, based on the most recent SEC filings. CAMP trades on the Nasdaq exchange and files with the SEC under CIK 1736730. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CAMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Camp4 Therapeutics Corp directly from SEC EDGAR. Camp4 Therapeutics Corp's 13F Pro composite quality score has ranged between 23 and 27 since 2026, currently 23.3 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Camp4 Therapeutics Corp

Quirks, history, and lore behind CAMP — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Like most clinical-stage biotechs, it generates minimal product revenue and funds its pipeline primarily through equity raises and partnerships — burning cash in pursuit of a big idea.
3
The History
Founded in the 2010s, it emerged from cutting-edge academic research into a largely unexplored layer of gene regulation that sits between DNA and protein.
4
The Secret
Its entire platform is built around RNA structure — specifically targeting the folded shapes RNA molecules form, rather than the sequences themselves, to control gene expression.
5
The Lore
The company's focus on RNA secondary structures puts it in rare scientific territory — most rivals chase DNA editing or linear RNA sequences, but this team is hunting the 3-D origami of the transcriptome.
6
The Giveaway
Its ticker literally spells out CAMP — short for a company whose name evokes an outdoor base and a gene-regulation frontier, Camp4 Therapeutics, pioneering the RNA structure medicine space.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.3M

Net Income

Q1 2026

$-18.3M

Free Cash Flow

Q1 2026

$-11.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+899.4% YoY

$3.5MFY 2025

FY23 $350.0KFY25 $3.5M

Net Income

-63.1% YoY

$-80.4MFY 2025

FY23 $-49.3MFY25 $-80.4M

Operating Income

-1.3% YoY

$-52.6MFY 2025

FY23 $-51.9MFY25 $-52.6M

EPS (Diluted)

+57.5% YoY

$-2.65FY 2025

FY23 $-6.24FY25 $-2.65

Total Assets

+114.4% YoY

$117.8MFY 2025

FY23 $54.9MFY25 $117.8M

Op. Cash Flow

+33.1% YoY

$-29.6MFY 2025

FY23 $-44.2MFY25 $-29.6M

Metric	FY 2025	FY 2023
Revenue	$3.5M +899.4%	$350.0K
Net Income	$-80.4M -63.1%	$-49.3M
Operating Income	$-52.6M -1.3%	$-51.9M
EPS (Diluted)	$-2.65 +57.5%	$-6.24
Total Assets	$117.8M +114.4%	$54.9M
Operating Cash Flow	$-29.6M +33.1%	$-44.2M

AI Insight: CAMP Financial Trends

Camp4 is burning equity steadily with no revenue traction — equity has collapsed from $63M in Q4 2024 to $31M in Q1 2026.

• Equity eroded from $63M in Q4 2024 to $31M in Q1 2026, a ~51% decline in five quarters.

• Revenue has flatlined at $0–$1M every quarter from Q4 2024 through Q1 2026 — no commercial growth visible.

• Operating cash outflow has ranged from -$10M to -$14M per quarter, except Q4 2025's unusual +$6M inflow.

⚠ Net loss spiked to -$40M in Q4 2025 vs. a -$13M run rate — the one-time driver warrants close scrutiny.

⚠ At $31M equity and ~$11M quarterly cash burn, runway is critically short absent new financing.

AI Insight: CAMP Ratio Trends

Sparse data limits analysis, but persistently deep negative ROA across all reported quarters signals Camp4 remains a pre-revenue, cash-burning clinical-stage company.

• ROA deteriorated from -67.8% in Q4 2024 to -98.2% in Q2 2025 before partially recovering to -69.5% in Q1 2026.

• ROE deepened sharply from -84.1% in Q4 2024 to -125.9% in Q2 2025, indicating accelerating equity erosion mid-period.

• Most ratio fields — OpMargin, NPM, D/E, ROIC — are absent across nearly all periods, reflecting pre-revenue stage with limited disclosures.

⚠ ROA improved to -69.5% in Q1 2026 from the -98.2% trough; monitor whether this reflects genuine burn-rate reduction or one-off timing.

⚠ No D/E data reported; debt capacity and runway visibility remain opaque and critical for a cash-consuming clinical-stage biotech.

Get alerted when CAMP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Camp4 Therapeutics Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CAMP

JANUS HENDERSON GROUP PLC
$27.9M6,307,636 sh
5AM Venture Management, LLC
$25.9M5,869,091 sh
FMR LLC
$21.8M4,933,432 sh
Vivo Capital, LLC
$18.7M4,246,568 sh
BALYASNY ASSET MANAGEMENT L.P.
$11.6M2,632,437 sh
Enavate Sciences GP, LLC
$9.7M2,190,920 sh
a16z Capital Management, L.L.C.
$9.4M2,125,339 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$8.6M1,960,784 sh
Trails Edge Capital Partners, LP
$8.6M1,939,563 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.8M1,534,768 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$27.9M	6,307,636
5AM Venture Management, LLC	$25.9M	5,869,091
FMR LLC	$21.8M	4,933,432
Vivo Capital, LLC	$18.7M	4,246,568
BALYASNY ASSET MANAGEMENT L.P.	$11.6M	2,632,437
Enavate Sciences GP, LLC	$9.7M	2,190,920
a16z Capital Management, L.L.C.	$9.4M	2,125,339
ADAGE CAPITAL PARTNERS GP, L.L.C.	$8.6M	1,960,784
Trails Edge Capital Partners, LP	$8.6M	1,939,563
VANGUARD CAPITAL MANAGEMENT LLC	$6.8M	1,534,768

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CAMP on your watchlist

Track score changes the day Camp4 Therapeutics Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CAMP a good stock to buy?

13F Pro's AI-powered analysis of Camp4 Therapeutics Corp (CAMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CAMP are available on the CAMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CAMP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CAMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Camp4 Therapeutics Corp's investment landscape.